CLEVELAND — Gene editing is the revolution in medical history and a groundbreaking trial is demonstrating how this technology could transform the way millions of Americans manage high cholesterol.

A Phase 1 clinical trial at Cleveland Clinic has shown that a single infusion of gene-editing therapy can significantly and permanently reduce cholesterol and triglyceride levels in patients whose conditions don't respond to standard medications.

The trial results, presented Saturday at the American Heart Association's Scientific Sessions 2025 and published simultaneously in the New England Journal of Medicine, showed the experimental CRISPR-Cas9 treatment reduced LDL cholesterol by approximately 50% and triglycerides by about 55% in study participants.

"This treatment is still very ea

See Full Page